The latest update is out from Imugene Limited ( (AU:IMU) ).
Imugene Limited has been granted a patent in India for its CF33 oncolytic virotherapy technology, extending its intellectual property protection globally. This patent, which lasts until 2037, strengthens Imugene’s position in key markets like the US and Japan, and underscores its commitment to advancing its oncolytic virotherapy pipeline. The CF33 technology, developed by Professor Yuman Fong, targets and destroys cancer cells while stimulating the immune system, potentially improving patient outcomes. This development is a significant step in Imugene’s mission to deliver next-generation immunotherapies worldwide.
More about Imugene Limited
Imugene Limited is a clinical-stage immuno-oncology company focused on developing innovative immunotherapies to activate the immune system against cancer. Their pipeline includes CAR T cell therapy azer-cel for blood cancers, multiple B-cell vaccine candidates, and the oncolytic virotherapy CF33 for various cancers. The company aims to transform cancer treatment with its novel therapies, supported by international cancer experts and clinical evidence.
YTD Price Performance: 70.0%
Average Trading Volume: 137,945
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $170.3M
See more data about IMU stock on TipRanks’ Stock Analysis page.